Quotient Limited Announces Opening of Office in Dubai, United Arab Emirates
May 17 2022 - 8:17AM
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics
company, today announced the opening of its new office in Dubai,
UAE, and the incorporation of its subsidiary Quotient Middle-East
and Africa FZ LLC, as part of its ongoing expansion plans to better
support customers in the region.
“We are very pleased to announce the opening of our new office
in Dubai, to reinforce growth opportunities in emerging markets,”
said Manuel O. Méndez, Chief Executive Officer of Quotient. “This
is the latest step in establishing a diversified global presence,
which is vital to our commercial strategy and our goal to improve
clinical practices and increase laboratory efficiencies across the
globe.”
Quotient has received the CE Mark for its MosaiQ Extended
Immunohematology Microarray, which substantially increases the
range of tests that can be run on its MosaiQ consolidated testing
platform. The Company is now commercializing the microarray for use
in the EU and other CE Mark recognizing geographies. Quotient is
also a leading global supplier of high-quality blood grouping
reagents for use in the transfusion diagnostics market.
"We already have a strong base of distributors we work with in
the Middle East and North Africa, thanks to our updated distributor
strategy model" said Mohammad El Khoury, Chief Commercial Officer
of Quotient. "Having received the CE Mark, we are now actively
discussing commercial distribution offers with potential partners
to expand our network across the EU, Middle East and Africa for the
MosaiQ solution. The addition of the new Dubai office will be a
major factor in driving our commercial achievements in the
region."
About Quotient Limited
Building on over 30 years of experience in
transfusion diagnostics, Quotient is a commercial-stage diagnostics
company committed to delivering solutions that it believes reshape
the way diagnostics are practiced. MosaiQ, Quotient’s proprietary
multiplex microarray technology, offers the world’s first fully
automated, consolidated testing platform, allowing for multiple
tests across different modalities. MosaiQ is designed to be a
game-changing solution, which Quotient believes will increase
efficiencies, improve clinical practice, deliver significant
workflow improvements, and create operational cost savings to
laboratories around the world. Quotient's operations are based in
Switzerland, Scotland, US and the UAE.
The Quotient logo, Quotient MosaiQ and MosaiQ
are registered trademarks or trademarks of Quotient Limited and its
subsidiaries in various jurisdictions.
CONTACT: Investor Relations,
ir@quotientbd.com; +41 22 545 52 26
Forward-Looking Statements
This news release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934 and
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements may include statements regarding our
expectations of continued growth, the development, regulatory
approval, commercialization and impact of MosaiQ and other new
products (including the potential for using the Company’s MosaiQ
technology to infectious disease diagnostics), current estimates of
fourth quarter and full year fiscal 2022 operating results and
expectations regarding our future funding sources. Such statements
are based on current assumptions that involve risks and
uncertainties that could cause actual outcomes and results to
differ materially. These risks and uncertainties, many of which are
beyond our control, include delays or denials of regulatory
approvals or clearances for products or applications; market
acceptance of our products; the impact of competition; the impact
of facility expansions and expanded product development, clinical,
sales and marketing activities on operating expenses; delays or
other unforeseen problems with respect to manufacturing, product
development or field trial studies; adverse results in connection
with any ongoing or future legal proceedings; continued or
worsening adverse conditions in the general domestic and global
economic markets, including as a result of the global COVID-19
pandemic; as well as the other risks set forth in the Company's
filings with the Securities and Exchange Commission. Investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Quotient
disclaims any obligation to update these forward-looking
statements.
The Quotient logo, Quotient MosaiQ and MosaiQ
are registered trademarks or trademarks of Quotient Limited and its
subsidiaries in various jurisdictions.
Quotient (NASDAQ:QTNT)
Historical Stock Chart
From Apr 2024 to May 2024
Quotient (NASDAQ:QTNT)
Historical Stock Chart
From May 2023 to May 2024